Michael Gelband’s Accelerate Diagnostics AXDX Stock Holding History

Michael Gelband’s Portfolio AXDX Stock Details AXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-4,000	Closed	-$743K	–	1521
2019 Q3	$743K	Buy	+4,000	New	+$773K	0.03%	490

Other funds holding AXDX

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

GAM

Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return

Baird Financial Group Milwaukee, Wisconsin $72.7B AUM 26.4% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Michael Gelband's AXDX Position: Q3 2021 in Review

Michael Gelband sold out of Accelerate Diagnostics (AXDX) in Q3 2021, closing a stake of 3,278 shares — an estimated $264K sold.

Michael Gelband first reported a position in AXDX in Q3 2020 and held it in 3 quarters. The position peaked at $264K in Q2 2021. 105 funds tracked by Wall St. Rank hold AXDX as of Q3 2021.

Michael Gelband reported no remaining Accelerate Diagnostics position as of Q3 2021 after selling out during the quarter.
Michael Gelband sold 3,278 Accelerate Diagnostics shares in Q3 2021, an estimated $264K.
Michael Gelband first reported a position in Accelerate Diagnostics in Q3 2020 and held it in 3 quarters.
Michael Gelband's Accelerate Diagnostics position peaked at $264K in Q2 2021.
105 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q3 2021.

Based on ExodusPoint Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.